90 results
S-8
EX-99.2
NGNE
Neurogene Inc
20 Feb 24
Registration of securities for employees
4:16pm
by a Participant (i) the Committee may determine that a leave of absence (including as a result of a Participant’s short-term or long-term disability
8-K
EX-10.6
NGNE
Neurogene Inc
19 Dec 23
Neurogene Doses First Patients in Phase 1/2 Trial of NGN-401 for the Treatment of Female Pediatric Patients with Rett Syndrome
7:31am
billion or with an average rating above investment grade by S&P (LT Local Issuer Credit Rating), Moody’s (Long Term Rating) and Fitch Ratings, Inc. (LT
8-K
EX-10.21
NGNE
Neurogene Inc
19 Dec 23
Neurogene Doses First Patients in Phase 1/2 Trial of NGN-401 for the Treatment of Female Pediatric Patients with Rett Syndrome
7:31am
by a Participant (i) the Committee may determine that a leave of absence (including as a result of a Participant’s short-term or long-term disability
425
mkqca
4 Dec 23
Business combination disclosure
5:14pm
8-K
EX-10.1
w4j763h
4 Dec 23
Other Events
5:10pm
S-4/A
cri wurgs
28 Sep 23
Registration of securities issued in business combination transactions (amended)
4:28pm
S-4
p2481y
18 Aug 23
Registration of securities issued in business combination transactions
6:19pm
425
pqp8 roc5
18 Jul 23
Business combination disclosure
4:02pm
425
sk4ai04gw6qrnza1fc1
18 Jul 23
Business combination disclosure
8:37am
8-K
EX-2.1
p2ac6i7ivc7ik82uk0sr
18 Jul 23
Neurogene and Neoleukin Announce Definitive Merger Agreement
8:34am
8-K
EX-10.1
66xlokd40d7m aukbqq9
18 Jul 23
Neurogene and Neoleukin Announce Definitive Merger Agreement
8:34am